Dabigatranate belongs to the new oral anticoagulant, synthetic direct thrombin inhibitor, which is a precursor drug of dabigatran and belongs to the non-peptide thrombin inhibitors. After oral administration, it is absorbed through the gastrointestinal tract and converted into, dabigatran with direct anticoagulant activity in the body. Dabigatran binds to the fibrin-specific binding site of thrombin and prevents the cleavage of fibrinogen into fibrin, thus blocking the final step of the coagulation waterfall network, i.e., thrombosis, and dabigatran can dissociate from the fibrin thrombin conjugate to exert reversible anticoagulant effects. Dabigatran is currently used to prevent stroke and systemic embolism in adults with non-valvular atrial fibrillation who have one or more of the following risk factors. These risk factors include patients with prior stroke, transient ischemic attack, or systemic embolism, patients with left ventricular ejection fraction <40%, patients with symptomatic heart failure, cardiac function class 2 or higher, age >75 years or older, or age 65 years or older with any of the following conditions, such as diabetes mellitus, coronary artery disease, or hypertension.